| Identification | Back Directory | [Name]
B I09 | [CAS]
1607803-67-7 | [Synonyms]
B I09
B I09,B I-09
7-(1,3-Dioxan-2-yl)-1,2,3,4-tetrahydro-8-hydroxy-5H-[1]benzopyrano[3,4-c]pyridin-5-one
5H-[1]Benzopyrano[3,4-c]pyridin-5-one, 7-(1,3-dioxan-2-yl)-1,2,3,4-tetrahydro-8-hydroxy- | [Molecular Formula]
C16H17NO5 | [MDL Number]
MFCD30742940 | [MOL File]
1607803-67-7.mol | [Molecular Weight]
303.31 |
| Chemical Properties | Back Directory | [Boiling point ]
486.5±45.0 °C(Predicted) | [density ]
1.44±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO:11.75(Max Conc. mg/mL);38.74(Max Conc. mM) | [form ]
Solid | [pka]
8.50±0.20(Predicted) | [color ]
Yellow to brown |
| Hazard Information | Back Directory | [Uses]
B I09, is a novel chromenone-based covalent inhibitors of IIRE-1 RNase. It Inhibits IRE-1/XBP1 pathway, and thus growth of human chronic lymphocytic leukemia (CLL) cells in vitro and promotes CLL regression in a mouse model. | [in vivo]
B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity[2]. | [storage]
4°C, protect from light |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|